Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 06:05 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
A Study of Reslizumab in Patients 12 Years of Age and Older With Severe Eosinophilic Asthma
NCT03052725 · Teva Branded Pharmaceutical Products R&D, Inc. · PHASE3 · terminated · last registry update 2022-12-14 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Parent Studies didn't meet their primary endpoint so study was terminated.” | – | Registry record, Teva Branded Pharmaceutical Products R&D, Inc. |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against IL5 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2023-08-07Phase 3 first posted: Guangdong Hengrui Pharmaceutical Co., Ltd, SHR-1703 + Mepolizumab Injection (NCT05979051)
- 2023-06-23Results posted on the registry: University of North Carolina, Chapel Hill, Mepolizumab 300 mg + Mepolizumab 100 mg (NCT03656380)
- 2022-06-21Results posted on the registry: National Institute of Allergy and Infectious Diseases (NIAID), Mepolizumab + Placebo (NCT03292588)
- 2022-04-19Phase 3 first posted: GlaxoSmithKline, Depemokimab (NCT05334368)
- 2022-03-16Phase 3 first posted: GlaxoSmithKline, Depemokimab (GSK3511294) + Placebo (NCT05281523)
- 2022-03-10Phase 3 first posted: GlaxoSmithKline, Depemokimab (GSK3511294) + Placebo (NCT05274750)
- 2022-03-03Phase 3 first posted: GlaxoSmithKline, Depemokimab + Mepolizumab (NCT05263934)
- 2022-02-17Phase 3 first posted: GlaxoSmithKline, GSK3511294 (Depemokimab) (NCT05243680)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision